Granules India Limited (NSE:GRANULES)

Market Cap	136.05B
Revenue (ttm)	48.42B
Net Income (ttm)	5.13B
Shares Out	n/a
EPS (ttm)	21.15
PE Ratio	26.53
Forward PE	21.34
Dividend	1.50 (0.26%)
Ex-Dividend Date	Jul 31, 2025

Volume	2,352,948
Average Volume	1,066,500
Open	568.85
Previous Close	566.40
Day's Range	552.25 - 568.85
52-Week Range	422.00 - 621.10
Beta	-0.11
RSI	52.95
Earnings Date	Nov 13, 2025

About Granules India

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1984
• Employees: 4,066
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GRANULES

Financial Performance

In 2024, Granules India's revenue was 44.82 billion, a decrease of -0.55% compared to the previous year's 45.06 billion. Earnings were 5.02 billion, an increase of 23.74%.